Arrowstreet Capital, Limited Partnership Cyma Bay Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $7.78 Million - $15.1 Million	-615,788 Reduced 98.01%	12,515 $296,000
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $6.82 Million - $11.1 Million	628,303 New	628,303 $9.37 Million
Q3 2020 Nov 12, 2020	SELL	$3.32 - $7.24 $3.44 Million - $7.5 Million	-1,036,294 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$1.41 - $4.25 $1.46 Million - $4.4 Million	1,036,294 New	1,036,294 $3.62 Million
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $23,031 - $37,218	-18,425 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.33 - $5.93 $24,505 - $109,260	18,425 New	18,425 $36,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.